Common use of Generic Competition Clause in Contracts

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Topotecan or sale of an approved equivalent to Sphingosomal Topotecan (collectively, “Approved Sphingosomal Topotecan Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Topotecan in such country during such calendar year will be reduced by [*] of the royalties payable to INEX pursuant to Section 3.3.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Topotecan or sale of an approved equivalent to Sphingosomal Topotecan (collectively, “Approved Sphingosomal Topotecan Equivalents”) in any country in the Territory, thenthem, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Topotecan in such country during such calendar year will be reduced by to [***] percent ([***]%) of the royalties payable to INEX pursuant to Section 3.3.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Topotecan Vinorelbine or sale of an approved equivalent to Sphingosomal Topotecan Vinorelbine (collectively, “Approved Sphingosomal Topotecan Vinorelbine Equivalents”) in any country in the Territory, thenthem, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Topotecan Vinorelbine in such country during such calendar year will be reduced by to [***] percent ([***]%) of the royalties payable to INEX pursuant to Section 3.3.2 3.2.2 for such calendar year, in such country.

Generic Competition. (a) If, during a given calendar year, there is sale of a generic Sphingosomal Topotecan or sale of an approved equivalent to Sphingosomal Topotecan (collectively, “Approved Sphingosomal Topotecan Equivalents”) in any country in the Territory, then, for such country, the total amount of royalties payable to INEX for the Net Sales of Sphingosomal Topotecan in such country during such calendar year will be reduced by [***] percent ([***]%) of the royalties payable to INEX pursuant to Section 3.3.2 for such calendar year, in such country.